Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 First-in-Human Study of PF-07328948 in Healthy Adults
NCT05654181Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07328948 in heart failure (HF) (3 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants Reporting Treatment-Emergent Adverse Events, Number of Participants With Clinical Laboratory Abnormalities and 4 more. Started Oct 2022; status: completed.
02
Drugs
PF-07328948
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05654181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654181.